Capricor Therapeutics Inc (CAPR)

[mick]

this is very possible now !!!!! the thing we have are 2nd phase of 20 new patients for review'

and 20
20 MORE ALSO; There is also a randomized, placebo-controlled trial
planned to treat patients with moderate and severe disease which is intended to be funded by non-equity capital such as grants.

USE OF PROCEEDS



We will receive no proceeds from the resale by the selling stockholders of the shares of our Common Stock issued upon the exercise of the Warrants. We may, however, receive up to approximately $5.4 million upon the cash exercise of the Warrants. We intend to use the proceeds received from any cash exercise of the Warrants to further develop our product candidates and for other general corporate and working capital purposes.



Our management will have broad discretion regarding the use of proceeds from the cash exercise of any of the Warrants, and investors will be relying on the judgment of our management regarding the application of the proceeds from the cash exercise of the Warrants. We may change the use of these proceeds from those described in this prospectus as a result of various factors such as competitive developments, the results of our early clinical development, manufacturing and commercialization efforts, the timing and progress of any partnering efforts, and other factors.